藍帆醫療(002382.SZ):控股股東完成2020年非公開發行可交債(第一期)
格隆匯 6 月 18日丨藍帆醫療(002382.SZ)公佈,公司於近日接到控股股東淄博藍帆投資有限公司(“藍帆投資”)的通知,獲悉其完成了2020年非公開發行可交換公司債券(第一期)發行工作。此次可交換債券具體發行情況如下:
1、債券簡稱:“20藍帆E1”,證券代碼“117164”;
2、發行期間:2020年6月15日至2020年6月15日;
3、實際募集資金規模:實際募集資金2億元,最終票面利率為3%;
4、換股價格:此次可交換債券的初始換股價格為24.15元/股,不低於募集説明書披露日前1個交易日、前20個交易日藍帆醫療(002382.SZ)股票收盤價均價中的最高者;
5、換股期限:2020年12月16日至2023年6月14日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.